- Shawn Thomas
- 5 minutes read
Medical record retrieval for clinical trials means obtaining the specific clinical documents needed to confirm eligibility and key safety facts, then handling those records in a way that meets privacy, security, and regulatory expectations.
Why record retrieval matters in clinical trials
Medical records are often the strongest evidence behind an inclusion or exclusion decision. FDA’s guidance on using electronic health record (EHR) data in clinical investigations emphasizes planning for EHR use as a data source, protecting data quality and integrity, and staying inspection ready. FDA’s electronic source data guidance similarly focuses on reliability, quality, integrity, and traceability from electronic source to regulatory submission.
Operationally, retrieval shifts work earlier. It helps teams confirm “must have” criteria before scheduling high-effort screening steps, which can reduce avoidable site burden and improve the participant experience.
Build a fit-for-purpose record package
A common pitfall is requesting the “entire chart” by default. A faster approach is to request only what you need to evaluate protocol criteria, then expand only if gaps remain.
Many studies can start with:
- Recent progress notes tied to the target condition
- Medication list and relevant procedure history
- Protocol-critical labs (with dates and units)
- Imaging or pathology reports when they gate eligibility
This targeted approach fits the intent of HIPAA’s minimum necessary principle for disclosures where the standard applies.
Choose the right legal pathway under HIPAA
In the U.S., record retrieval usually involves protected health information (PHI). HIPAA allows research-related use or disclosure of PHI through multiple pathways, and the correct choice depends on what the team is doing.
A HIPAA Authorization signed by the participant is common once an individual is identified and engaged, and HHS notes that HIPAA does not prohibit conditioning research enrollment on signing an authorization to use or disclose pre-existing health information.
When an IRB or Privacy Board approves it, HIPAA also allows certain research disclosures without individual authorization through a waiver or alteration, and HHS indicates covered entities may reasonably rely on waiver documentation for research disclosures under the research provision.
For feasibility, protocol development, or recruitment planning, HIPAA’s “preparatory to research” provision can allow access when the researcher represents the access is solely preparatory, that PHI will not be removed from the covered entity, and that the PHI is necessary.
When direct identifiers can be excluded, a limited data set with a data use agreement can support research, public health, or operations. If records include federally protected substance use disorder information, additional requirements under 42 CFR Part 2 may apply.
Participants can also request and share their own records. HHS explains that covered entities must act on a HIPAA access request within 30 days, with one possible 30-day extension if they provide a written delay notice.
Interoperability is improving retrieval, but gaps remain
Federal policy is pushing health data access toward APIs and easier exchange. ONC’s Cures Act Final Rule supports secure access, exchange, and use of electronic health information, promotes standardized APIs, and addresses information blocking. CMS’s Interoperability and Patient Access Final Rule similarly advances APIs aimed at improving patient access and electronic exchange.
Health data is also increasingly electronic at the source. The CDC’s 2024 National Electronic Health Records Survey found that 95.0% of U.S. office-based physicians had adopted EHRs, with 83.6% using a certified EHR. Even with high adoption, “digital” does not always mean “interoperable.”
At the network level, ONC describes TEFCA as a nationwide framework intended to remove barriers to electronic sharing among providers, patients, public health agencies, and payers. A December 2024 final rule strengthened TEFCA-related definitions and information blocking provisions, effective January 15, 2025.
Exchange remains uneven across care settings. ONC found that 70% of hospitals engaged in all four interoperability domains in 2023 and also noted weaker exchange with behavioral health and long-term/post-acute care partners.
Security and data quality controls to bake in from day one
Record retrieval should be treated as regulated data handling. HIPAA’s Security Rule sets national standards for safeguarding electronic protected health information (ePHI) and requires administrative, physical, and technical safeguards from covered entities and business associates. NIST’s HIPAA Security Rule resource guide reiterates that ePHI must be protected against reasonably anticipated threats and impermissible uses or disclosures.
If third parties handle PHI during retrieval, the workflow should be supported by appropriate HIPAA business associate agreements that limit and safeguard permitted uses and disclosures.
Strong retrieval processes also include role-based access, secure transmission and storage, audit trails, and checks that records match the right patient, facility, and date range. These controls support FDA expectations for data integrity when EHR data is used as electronic source data.
Conclusion
Medical record retrieval for clinical trials works best when it is planned like any other study process: define a fit-for-purpose record set, use the HIPAA pathway that matches the activity, and treat every step as a privacy and security event. Interoperability is improving access, but trial teams still need clear requests, clear permissions, and strong controls to turn records into reliable eligibility decisions.